Supernus Pharmaceuticals signed a definitive agreement to acquire fellow biopharmaceutical company Sage Therapeutics for $8.50 a share in a deal worth an initial $561 million.The terms of the deal also include one non-tradable contingent value right (CVR) payable upon achieving certain sales goals,

Sage Therapeutics SAGE announced that Supernus Pharmaceuticals SUPN has agreed to acquire SAGE through a tender offer of $8.50 per share in cash, totaling around $561 million. Additionally, shareholders will receive a non-tradable contingent value right (CVR) worth up to $3.

Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential. Read my analysis on this acquisition.